From: Budget impact analysis of breast cancer medications: a systematic review
Study | Year | Country | Funding | Perspective | Study type | Study base | Intervention | Comparator | Population | Population size |
---|---|---|---|---|---|---|---|---|---|---|
Ivanov et al. [40] | 2021 | Russia | N.R | Federal Compulsory Health Insurance Fund | CMA + BIA | Model | PO vinorelbine | Ixabepilone | Metastatic BC | 1000 hypothetical patients |
Elsamany et al. [37] | 2020 | Saudi Arabia | Roche Products Saudi Arabia | Governmental health sector | BIA only | Model | SC trastuzumab | IV trastuzumab | HER 2 + BC | 394 newly diagnosed cases/ year |
Pouwels et al. [27] | 2020 | Netherlands | Netherlands Organization for Health Research and Development, Eisai, Novartis BV, Roche, Pfizer and Eli Lilly | Dutch societal | CEA + BIA | Real-world | Eribulin | Non-eribulin chemotherapy | The Southeast Netherlands advanced BC registered patients | – |
Genuino et al. [38] | 2019 | Philippines | Mahidol University and the International Decision Support Initiative (iDSI) | Healthcare system and societal | CUA + BIA | Model | Adjuvant trastuzumab | Standard chemotherapy alone | HER 2 +  early-stage BC | 64,046 |
Prevalent | ||||||||||
Cases in 5Â years, 21,057 | ||||||||||
New cases (23.17% HER 2 + , 80% early stage) | ||||||||||
Avxentyev et al. [41] | 2019 | Russia | Pfizer | Russian healthcare system | CMA + BIA | Model | CDK 4/6 inhibitor + letrozole | Another CDK 4/6 inhibitor + letrozole | HR + HER 2 -advanced BC | 8098–8221 newly diagnosed patients/ year |
Lee et al. [28] | 2019 | 28 European Countries | Chung-Ang University research | Payer | BIA only | Model | Biosimilar Trastuzumab (CT-P6) | Originator trastuzumab | HER 2 + BC | Early BC: 79,723 (2018) Metastatic BC: 14,844 (2018) |
Mistry et al. [34] | 2019 | USA | Novartis | US payer | BIA only | Model | Ribociclib + letrozole | Letrozole alone, palbociclib + letrozole, fulvestrant + anastrozole, fulvestrant alone, exemestane, tamoxifen, anastrozole alone, palbociclib + Fulvestrant, Fulvestrant + letrozole, and eribulin | Post-menopausal women with HR + /HER2 -advanced /metastatic BC | 263 cases in a cohort of 1 million members at first year and increase in subsequent years |
Clarke et al. [33] | 2017 | UK | No fund | English NHS payer | CEA + BIA | Model | Different durations of adjuvant | – | Early BC | – |
trastuzumab | ||||||||||
Cesarec et al. [26] | 2017 | Croatia | No fund | Public healthcare | BIA only | Model | Biosimilar Trastuzumab | – | BC | 479 cases in 1 year |
Lewis et al. [39] | 2015 | Kazakhstan | Novartis Pharma AG | N.R | BIA only | Model | Everolimus + letrozole/anastrozole | Letrozole/anastrozole, | Post-menopausal HR + HER2 -advanced BC | 776 prevalent, and 133, 145, 157, and 170 newly diagnosed in 2015–2018 |
Chemotherapy, | ||||||||||
Tamoxifen | ||||||||||
Benjamin et al. [30] | 2013 | France | GSK | French National Health Insurance | BIA only | Model | Trastuzumab-based therapy | Lapatinib + capecitabine | HER2-positive metastatic BC | 4182 cases (73% trastuzumab-based therapy, 27% lapatinib + capecitabine) |
Xie et al. [43] | 2013 | US | Novartis | US payer | BIA only | Model | Exemestane + everolimus | Exemestane Fulvestrant Tamoxifen | HER2-positive advanced BC | 72 cases / 1 million receiving their first treatment after letrozole or anastrozole failure, and 159 cases / 1 million receiving a second treatment after failing letrozole or anastrozole and the first treatment |
Purmonen et al. [31] | 2010 | Finland | Finnish Office for Health Technology Assessment (Finohta) | Single hospital district | BIA only | Model | Trastuzumab | – | Early BC | 86.6/100,000 in 2006 |
Ho et al. [36] | 2009 | US | Bristol-Myers Squibb Company (BMS) | Payer | BIA only | Model | Ixabepilone | Various anti-cancer medications | Treatment-resistant metastatic BC | 570 cases/1 million |
Neyt et al. [32] | 2008 | Belgium | N.R | Payer | CEA + BIA | Model | Trastuzumab | ST | Early BC | – |
Millar et al. [42] | 2007 | Australia | N.R | Australian health system | CEA + BIA | Model | Trastuzumab | ST | Early BC | – |
Marchetti et al. [29] | 2004 | Italy | AstraZeneca SpA | Italian National Health Service | CUA + BIA | Model | Third-Generation Aromatase | Tamoxifen, megestrol, paclitaxel, docetaxel, vinorelbine | Advanced BC | – |
Inhibitors |